Neuren Pharmaceuticals: Receives US$10m milestone payment

Neuren Pharmaceuticals Receives US$10m milestone payment

  • Neuren Pharmaceuticals (NEU) receives a US$10 million (A$16 million) milestone payment from its partner, Acadia Pharmaceuticals
  • The payment follows the US FDA’s acceptance for review of Acadia’s new drug application for trofinetide, which works to treat Rett syndrome
  • Acadia has exclusive rights to develop and commercialise trofinetide in North America, while Neuren holds all rights to the treatment outside of this
  • If the new drug application (NDA) is approved by the FDA, the next potential milestone payment to Neuren would be US$40 million (A$62 million), which would be payable following the first commercial sale of trofinetide in the United States
  • NeurenPharmaceuticals dips 0.13 per cent to trade at $7.51 at 1:00 pm AEDT
Steve Sam
Steve Sam
Steve Sam is a financial reporter, analyst, and commentator with a strong focus on banking technology, digital payments, and the future of financial services.

You May Also Like

Venmo Strengthens Global Transfers by Allowing Payments to PayPal Accounts

Venmo users can now send money internationally to PayPal accounts. Highlights: Venmo now allows users to send money to...

Talos and Nasdaq Strengthen On-Chain and Off-Chain Collateral Workflow

New partnership enhances digital asset handling and collateral management. Highlights: Talos and Nasdaq collaborate to streamline collateral workflows.Partnership aims...

FCA Restricts Use of Sensitive Data in AI Trial with Palantir

Regulatory concerns arise over data handling protocols in AI trials. Highlights: FCA criticized for using sensitive data in AI...

Bank of Ireland Strengthens AI Readiness for Staff Training

New initiatives prepare employees for an AI-driven banking landscape. Highlights: Bank of Ireland launches AI training initiatives for staff.Employees...